The Foundation is funding a research project on bladder cancer

Since 2017, the team of researchers from the CHUS Research Center working on this project, composed of Dr. Claudio Jeldres and researchers Martin Bisaillon and François-Michel Boisvert, has identified several samples that have allowed the discovery of a combination of biomarkers that allow the discovery of a combination of biomarkers to identify all aggressive tumors.

“For some patients, the presence of blood in the urine is a sign of bladder cancer. Currently, cytoscopy is the only examination that allows this diagnosis. However, it is invasive and expensive. We want to be able to identify these patients even before cytoscopy.”

“The need to quickly identify these high-risk users is urgent. With our project, we want to be able to create an easy to use and efficient test that will be used to prioritize these people. In addition, the costs associated with the diagnosis, treatment, and follow-up of bladder cancers are currently the highest in Canada. A rapid detection test would significantly reduce these costs, in the diagnosis and follow-up phases.”

— Dr. Claudio Jeldres, urologist and project manager.

‍

Bladder cancer is the 5th most common cancer in Canada and 75% of affected patients are men. Current diagnostic methods are painful, invasive, and expensive.

For two years, we have been organizing the White Shirt event for the benefit of the Human Health Fund, which allowed us to finance this project. In addition to the generosity of the participants who care about the cause at heart, the Foundation cannot ignore the major financial contribution of the Laroche Group in connection with projects related to diseases affecting mainly men.